Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome

Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome

SAN DIEGO, July 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that its major investment AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Services...
AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +2.42% a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept...
Amyotrophic Lateral Sclerosis (ALS) and Psoriasis Patients Receive Brazilian Government Permission to Be Treated with Medical Marijuana, Inc. Subsidiary, HempMeds® Brasil, Flagship Product RSHO™

Amyotrophic Lateral Sclerosis (ALS) and Psoriasis Patients Receive Brazilian Government Permission to Be Treated with Medical Marijuana, Inc. Subsidiary, HempMeds® Brasil, Flagship Product RSHO™

Brazilian Doctors Have Been Prescribing RSHO™ to Treat Patients Suffering From Effects of ALS and Psoriasis SAN DIEGO, July 19, 2017 — Medical Marijuana, Inc. (MJNA) is the first publicly traded cannabis company in the United States. Its subsidiary HempMeds®...